Consensus document of FCSA, SIMeL, SIBioC e CISMEL on laboratory monitoring of novel oral anticoagulant drugs
27/03/2018
Document pubblished on Riv Ital Med Lab 2013;9:131–133
https://link.springer.com/content/pdf/10.1007%2Fs13631-013-0014-2.pdf
Oral anticoagulant therapy (OAT) is used to pre- vent and treat thromboembolic diseases. The new oral anti- coagulants (NOAs) can be prescribed at fixed dosage with- out adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the con- sensus document of three Italian scientific societies deal- ing with laboratory issues in thrombosis and haemostasis. It is aimed at reviewing (i) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apix- aban); (ii) the patients to be investigated and (iii) the timing of investigation.